Home/Pipeline/Paltusotine (CRN00808)

Paltusotine (CRN00808)

Acromegaly

Phase 3Active (NDA Preparation)

Key Facts

Indication
Acromegaly
Phase
Phase 3
Status
Active (NDA Preparation)
Company

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is building a premier, endocrine-rooted global pharmaceutical company dedicated to improving the lives of patients with endocrine disorders. Founded by scientists with a proven track record in GPCR drug discovery, the company has advanced a pipeline of novel, oral nonpeptide therapies targeting significant unmet needs. With a lead program in Phase 3 for acromegaly and a growing pipeline, Crinetics is positioned to become a leader in next-generation endocrine care.

View full company profile

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is building a premier, endocrine-rooted global pharmaceutical company dedicated to improving the lives of patients with endocrine disorders. Founded by scientists with a proven track record in GPCR drug discovery, the company has advanced a pipeline of novel, oral nonpeptide therapies targeting significant unmet needs. With a lead program in Phase 3 for acromegaly and a growing pipeline, Crinetics is positioned to become a leader in next-generation endocrine care.

View full company profile

Other Acromegaly Drugs

DrugCompanyPhase
Acromegaly TreatmentsRecordatiCommercial